Reduced Mortality and Severe Disability Rates in the SENTIS Trial

REFERENCES

1. 1.↵
   1. Shuaib A,
   2. Bornstein NM,
   3. Diener HC,
   4. et al

   . Partial aortic occlusion for cerebral perfusion augmentation: Safety and Efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke 2011;42:1680–90

   Abstract/FREE Full Text
2. 2.↵
   1. Hammer M,
   2. Jovin T,
   3. Wahr JA,
   4. et al

   . Partial occlusion of the descending aorta increases cerebral blood flow in a nonstroke porcine model. Cerebrovasc Dis 2009;28:406–10

   CrossRefPubMed
3. 3.↵
   1. Emery DJ,
   2. Schellinger PD,
   3. Selchen D,
   4. et al

   . Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke 2011;42:1135–37

   Abstract/FREE Full Text
4. 4.↵
   1. Hammer MD,
   2. Schwamm L,
   3. Starkman S,
   4. et al

   . Safety and feasibility of NeuroFlo use in eight- to 24-hour ischemic stroke patients. Int J Stroke 2012;7:655–61

   CrossRefPubMed
5. 5.↵
   1. Liebeskind DS

   . Aortic occlusion for cerebral ischemia: from theory to practice. Curr Cardiol Rep 2008;10:31–36

   CrossRefPubMed
6. 6.↵
   1. Schellinger PD,
   2. Bath PM,
   3. Lees KR,
   4. et al

   . Assessment of additional endpoints for trials in acute stroke: what, when, where, in who? Int J Stroke 2012;7:227–30

   PubMed
7. 7.↵
   1. Lees KR,
   2. Bath PM,
   3. Schellinger PD,
   4. et al

   . Contemporary outcome measures in acute stroke research: choice of primary outcome measure. Stroke 2012;43:1163–70

   Abstract/FREE Full Text
8. 8.↵
   1. Bath PM,
   2. Lees KR,
   3. Schellinger PD,
   4. et al

   . Statistical analysis of the primary outcome in acute stroke trials. Stroke 2012;43:1171–78

   Abstract/FREE Full Text
9. 9.↵
   1. Davis SM,
   2. Donnan GA,
   3. Parsons MW,
   4. et al

   . Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol 2008;7:299–309

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Thomalla GJ,
    2. Kucinski T,
    3. Schoder V,
    4. et al

    . Prediction of malignant middle cerebral artery infarction by early perfusion- and diffusion-weighted magnetic resonance imaging. Stroke 2003;34:1892–99

    Abstract/FREE Full Text
11. 11.↵
    1. Albers GW,
    2. Thijs VN,
    3. Wechsler L,
    4. et al

    . Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508–17

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Mlynash M,
    2. Lansberg MG,
    3. De Silva DA,
    4. et al

    . Refining the definition of the malignant profile: insights from the DEFUSE-EPITHET pooled data set. Stroke 2011;42:1270–75

    Abstract/FREE Full Text
13. 13.↵
    1. Juttler E,
    2. Schellinger PD,
    3. Aschoff A,
    4. et al

    . Clinical review: therapy for refractory intracranial hypertension in ischaemic stroke. Crit Care 2007;11:231

    CrossRefPubMed
14. 14.↵
    1. Vahedi K,
    2. Hofmeijer J,
    3. Juettler E,
    4. et al

    . Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 2007;6:215–22

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Steiner T,
    2. Mendoza G,
    3. De Georgia M,
    4. et al

    . Prognosis of stroke patients requiring mechanical ventilation in a neurological critical care unit. Stroke 1997;28:711–15

    Abstract/FREE Full Text